• Saracatinib (AZD0530): Mechanism and Evidence Scope

  2026-10-16

  Saracatinib (AZD0530) is identified by APExBIO as a dual Src-family kinase and Abl inhibitor. The cited product description reports biochemical potency, pathway-associated molecular changes, cancer-cell phenotypes, and tumor growth inhibition in xenograft models, but no identity-matched research paper, effect-size dataset, comparator details, or independent validation is available in the cited material.

• DL-AP5: What the Record Establishes

  2026-10-16

  The cited APExBIO page identifies DL-AP5 as catalog item B6204, but the available product information does not document a molecular identity beyond the product name, a mechanism, a measurement principle, or research outcomes. No identity-matched study is available here, so mechanistic and performance claims would be premature.

• Annexin V-HF647/PI Kit: Evidence Boundaries

  2026-10-15

  The APExBIO listing identifies K2259 as an Annexin V-HF647/PI apoptosis kit, but the available product information contains no technical description, matched publication, performance data, or product-specific validation. Its name supports only a conceptual two-signal measurement overview; it does not establish assay mechanism, thresholds, specificity, or applicability in a particular model.

• Protein A/G Magnetic Beads: Scope and Evidence

  2026-10-15

  APExBIO describes Protein A/G Magnetic Beads (SKU K1305) as recombinant Protein A and Protein G ligands covalently attached to magnetic particles for Fc-mediated IgG capture. The documented material supports a plausible affinity-separation role in antibody purification and immunocapture assays, but no identity-matched study, quantitative performance data, or direct product comparison is available here.

• Medroxyprogesterone Acetate: Mechanism and Scope

  2026-10-14

  A source-bounded overview of medroxyprogesterone acetate (MPA), covering its documented identity, receptor-linked mechanism, reported renal and neurobiological observations, and the limits imposed by the absence of an identity-matched research paper.

• GBA1 mRNA in Gaucher Disease: Promise and Limits

  2026-10-14

  A 2026 preclinical report found that redesigned human GBA1 mRNA increased glucocerebrosidase expression and restored disease-related cellular phenotypes, with detectable enzyme activity in mouse liver and spleen after lipid-nanoparticle delivery. The findings support biological feasibility, but they do not establish clinical efficacy, neurological benefit, or long-term safety. 4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) is relevant as a conceptual fluorogenic substrate for β-glucosidase activity assays, although the supplied study does not document its use.

• EPZ5676 and DOT1L: What the Evidence Supports

  2026-10-13

  EPZ5676 is described by APExBIO as a selective DOT1L inhibitor, while recent peer-reviewed work links DOT1L inhibition to innate immune signaling and lenalidomide response in multiple myeloma models. The evidence supports a mechanistic research framework, but does not establish that EPZ5676 was used in that study, nor that findings in myeloma extend directly to MLL-rearranged leukemia or clinical treatment.

• Fabp4 CRISPRi in Obesity: Evidence and Limits

  2026-10-13

  A preclinical mouse study reported that adipose-targeted CRISPR interference against Fabp4 reduced several obesity-associated phenotypes. The findings support a proof of concept for tissue-directed gene repression, but they do not establish clinical efficacy, long-term safety, or any role for Silybin A or Silymarin.

• Rottlerin and Viral Entry: What the Evidence Shows

  2026-10-12

  A published grass carp reovirus study associated Rottlerin sensitivity with viral entry and replication in a fish kidney cell model, but pharmacological inhibition alone does not establish PKCδ as the responsible mechanism. The evidence supports a model involving dynamin-, endosomal-acidification-, and clathrin-associated processes, while leaving substantial questions about off-target effects, cytotoxicity, temporal resolution, and applicability beyond the tested cell system.

• BAP1 and Disulfidptosis: What the Evidence Shows

  2026-10-12

  A 2024 Oncogenesis study links BAP1 to resistance against disulfidptosis through regulation of SLC7A11-associated cystine stress and NADPH status. The findings support a mechanistic model, but the causal basis of NADPH regulation, pathway specificity, and clinical applicability remain unresolved.

• L-Ornithine in Realgar Neurotoxicity Research

  2026-10-11

  A source-grounded overview of a 2025 preclinical study linking hepatic OTC disruption, ornithine accumulation, astrocyte glycolysis, and realgar-associated CNS toxicity, with emphasis on evidence strength, provenance, and limits of translation.

• WRN–MSI Synthetic Lethality in Colon Cancer

  2026-10-10

  Hao and colleagues show that Werner helicase loss selectively kills microsatellite-unstable colorectal cancer cells through a p53–PUMA apoptotic program. Genetic, cellular, xenograft, and patient-derived models support WRN as a preclinical target in p53-wild-type MSI tumors, while also defining important limits for interpreting ML216-based pharmacology.

• FADD–Caspase-8–cFLIP DED Assembly Explained

  2026-10-09

  The 2024 study resolves previously unavailable structural details of human FADD–procaspase-8–cFLIP death-effector domain complexes using X-ray crystallography and cryo-electron microscopy. Its findings clarify how DED architecture can support limited caspase-8 activation, apoptosis regulation, and suppression of RIPK1-linked necroptotic signaling, while defining the boundaries between structural evidence and broader cancer applications.

• Praeruptorin A and ERK/MMP1 in HCC Metastasis

  2026-10-09

  Yu and colleagues showed that praeruptorin A suppresses migration and invasion of human hepatocellular carcinoma cells without producing the main signs of cytotoxicity in the tested models. The study’s central contribution is mechanistic: ERK pathway activation was linked to reduced MMP1 expression, providing a testable explanation for the compound’s antimetastatic activity while remaining limited to an in vitro evidence base.

• miR-3180, Lipid Metabolism, and HCC Progression

  2026-10-08

  Hong et al. identify miR-3180 as a regulator that links two lipid-acquisition routes in hepatocellular carcinoma: de novo fatty-acid synthesis through SCD1 and extracellular fatty-acid uptake through CD36. The study combines patient-tissue associations, molecular target analysis, cell-based phenotyping, and xenograft evidence, while also highlighting the limits of translating these findings into a therapeutic or prognostic application.

3662 records 1/245 page Next 12345 下5页 Last page